Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arvinas, Inc.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Korea's SK Group expands its biopharma business via a sizable investment in Roivant's protein degradation platform, through which the partners aim to progress candidates in cancer, immunology and neurology, with the first entering the clinic next year.
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.
- Large Molecule
- Other Names / Subsidiaries
- Arvinas LLC